• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Martinez Maria E

    9/5/25 4:04:08 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care
    Get the next $CATX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Martinez Maria E

    (Last) (First) (Middle)
    C/O PERSPECTIVE THERAPEUTICS, INC.
    2401 ELLIOTT AVENUE, SUITE 320

    (Street)
    SEATTLE WA 98121

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Perspective Therapeutics, Inc. [ CATX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock option (right to buy) $3.38 09/03/2025 A 75,000 (1) 09/03/2035 Common Stock 75,000 $0 75,000 D
    Explanation of Responses:
    1. Options vest and become exercisable over three years in 36 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each such vesting date.
    /s/ Maria E Martinez by Chris Nenno, as Attorney-in-Fact 09/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CATX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CATX

    DatePrice TargetRatingAnalyst
    3/13/2025$10.00Buy
    H.C. Wainwright
    3/7/2025$15.00Sector Outperform
    Scotiabank
    11/25/2024$24.00 → $5.00Buy → Neutral
    BofA Securities
    10/24/2024$20.00Buy
    UBS
    10/1/2024$25.00Outperform
    Wedbush
    9/25/2024$21.00Buy
    Truist
    7/25/2024$24.00Buy
    BofA Securities
    5/9/2024Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CATX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

    SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company's Board of Directors, effective today. Ms. Martinez-Davis currently serves as President of GSK's U.S. Commercial business, a position she has held since September 2019. In that role, she leads a robust and complex business portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin

    9/3/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics to Participate in Upcoming September Conferences

    SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences. Cantor Global Healthcare Conference – Fireside ChatDate: Thursday, September 4, 2025Time: 1:00 p.m. - 1:30 p.m. ETLocation: New York, NY Morgan Stanley 23rd Annual Global Healthcare ConferenceDate: Tuesday, September 9, 2025Location: New York, NY OPCO Targeted Radiopharmaceutical Therapies in Oncology Sum

    8/26/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Perspective Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $10.00

    3/13/25 7:26:51 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Scotiabank initiated coverage on Perspective Therapeutics with a new price target

    Scotiabank initiated coverage of Perspective Therapeutics with a rating of Sector Outperform and set a new price target of $15.00

    3/7/25 8:03:16 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Perspective Therapeutics from Buy to Neutral and set a new price target of $5.00 from $24.00 previously

    11/25/24 7:39:30 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Sendek Joel

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    9/5/25 4:06:51 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Sendek Joel

    3 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    9/5/25 4:05:22 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Martinez Maria E

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    9/5/25 4:04:08 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    SEC Filings

    View All

    Perspective Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    9/4/25 7:04:41 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    9/3/25 7:04:59 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    9/2/25 7:00:38 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    4/1/25 6:44:41 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Director Williamson Robert F Iii bought $132,151 worth of shares (60,337 units at $2.19), increasing direct ownership by 124% to 108,982 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    4/1/25 5:04:49 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Graham Juan bought $74,946 worth of shares (33,333 units at $2.25), increasing direct ownership by 1,649% to 35,354 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    4/1/25 5:03:59 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Leadership Updates

    Live Leadership Updates

    View All

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

    SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company's Board of Directors, effective today. Ms. Martinez-Davis currently serves as President of GSK's U.S. Commercial business, a position she has held since September 2019. In that role, she leads a robust and complex business portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin

    9/3/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

    6/24/25 12:52:00 PM ET
    $AUTL
    $CATX
    $INDP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $CATX
    Financials

    Live finance-specific insights

    View All

    Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

     Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were presented[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities and no discontinuations due to adverse events observed among a total of 42 patients who received at least one treatmentFour of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. Three of those patients experienced confirmed response and remained in response. One new first response is subject

    5/30/25 5:21:00 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

      Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212Pb]VMT-α-NET[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Coh

    1/24/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025

    SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated interim results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET (NCT05636618) has been accepted as a poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) taking place on January 23-25, 2025 in San Francisco, CA. The poster presentation entitled "Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)" will

    1/22/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Perspective Therapeutics Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 6:14:40 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

    SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 4:05:13 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

    SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/7/24 9:24:55 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care